Home Cart Sign in  
Chemical Structure| 676596-65-9 Chemical Structure| 676596-65-9

Structure of 1-Azakenpaullone
CAS No.: 676596-65-9

Chemical Structure| 676596-65-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

1-Azakenpaullone (1-Akp) is a highly selective, ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 18 nM.

Synonyms: 1-Akp

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 1-Azakenpaullone

CAS No. :676596-65-9
Formula : C15H10BrN3O
M.W : 328.16
SMILES Code : BrC1=CC=C2C(C(CC(NC3=C4N=CC=C3)=O)=C4N2)=C1
Synonyms :
1-Akp
MDL No. :MFCD09037522

Safety of 1-Azakenpaullone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of 1-Azakenpaullone

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

Target
  • GSK-3β

    GSK-3β, IC50:18 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Embryonic chick atrial myocytes 2-5 μM 24 hours To investigate the inhibitory effect of Kenpaullone on GSK3β and its impact on SREBP-1 and GIRK4 expression. Results showed that Kenpaullone dose-dependently increased the expression of nSREBP-1 and GIRK4. PMC4030105
Islet cells 10 µM 24 hours To evaluate the effect of 1-AKP on insulin secretion in islet cells. Results showed that islets from 1-AKP-treated c-KitWv/+ mice exhibited a significant increase in insulin secretion in response to 22 mM glucose, with a 2-fold increase compared to the untreated group. PMC3940483
HEK 293T cells 5 μM 24 hours To investigate the effect of ubiquitination on PXR protein levels, results showed that MG-132 effectively stabilized PXR protein. PMC8773821
HepG2 cells 5 μM 24 hours To investigate the effect of CDK inhibitors on PXR protein levels, results showed that kenpaullone significantly increased PXR protein levels. PMC8773821
RAW 264.7 macrophages 150 nM 24 hours To investigate the effect of 1-Azakenpaullone on RANKL-induced NFATc1 nucleotranslocation, results showed that 1-Azakenpaullone significantly reversed the inhibitory effects of fucoidan on NFATc1 phosphorylation and nucleotranslocation. PMC6627629
Rat primary cortical neurons 0.1 µM, 0.2 µM, 0.5 µM 3 days Enhanced Kcc2 mRNA expression in a dose-dependent manner PMC8551327
Primary cortical neurons 0.25–2 μM 36 hours KEN enhanced ADAM10 protein levels PMC10953581
HT22 cells 0.25–2 μM 36 hours KEN enhanced ADAM10 protein levels PMC10953581
HEK293 cells 0.25–2 μM 36 hours KEN enhanced ADAM10 protein levels PMC10953581
SH-SY5Y cells 0.25–2 μM 36 hours KEN significantly increased m-ADAM10 protein levels PMC10953581
Rat islet cells 5, 10, 15 µM 4 days To assess DNA synthesis and cell cycle progression. Results showed that 1-Akp significantly increased DNA synthesis, which was sensitive to rapamycin. PMC2646065
Human islet cells 5, 10, 15 µM 4 days To assess DNA synthesis, cell cycle progression, and β-cell proliferation. Results showed that 1-Akp significantly enhanced DNA synthesis, which was sensitive to rapamycin. PMC2646065
Adult human skin fibroblasts 1 µM starting at 14 dpi Kenpaullone significantly promotes the survival of ALS-hiMNs, enhances dendritic outgrowth and branching, rescues soma size, completely normalizes excitability, and restores the ability to form NMJs and control muscle activity. PMC4706770
Human fetal cortical neurons 50, 100, 400 nM 2-4 days Enhanced KCC2 mRNA and protein expression PMC8551327

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Nerve constriction injury pain model and bone cancer pain model Intraperitoneal and intrathecal injection 10-30 mg/kg Daily injections for 7-14 days KP significantly alleviated neuropathic pain and bone cancer pain, and repaired Kcc2 expression deficits in the spinal cord dorsal horn PMC8551327
Mice C-KitWv/+ male mice Intraperitoneal injection 2mg/kg Every other day for 2 weeks To evaluate the effect of 1-AKP on glucose metabolism and β-cell function in c-KitWv/+ mice. Results showed that 1-AKP treatment significantly improved fasting blood glucose levels, glucose tolerance, and insulin secretion, and increased β-cell mass and proliferation in c-KitWv/+ mice. PMC3940483
Zebrafish Zebrafish lateral-line neuromasts Immersion 30–50 µM 20 hours Evaluating the protective effect of kenpaullone against cisplatin-induced hair cell loss in zebrafish lateral-line neuromasts, results showed kenpaullone significantly reduced hair cell loss. PMC5881471
FVB mice Cisplatin-induced ototoxicity model Transtympanic injection 50 μM 1 hour before and 24 hours after cisplatin administration Evaluated the protective effect of 1-Azakenpaullone against cisplatin-induced ototoxicity, showing significant reduction in hearing loss. PMC6443376
APP/PS1 mice Alzheimer's disease model Intraperitoneal injection 7 mg/kg Every other day for 2 months KEN promoted ADAM10 expression and improved cognitive functions PMC10953581

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.05mL

0.61mL

0.30mL

15.24mL

3.05mL

1.52mL

30.47mL

6.09mL

3.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories